Affinity Asset Advisors LLC Increases Stock Holdings in Avalo Therapeutics, Inc. (NASDAQ:AVTX)

Affinity Asset Advisors LLC grew its holdings in Avalo Therapeutics, Inc. (NASDAQ:AVTX - Free Report) by 1,123.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 550,765 shares of the company's stock after acquiring an additional 505,765 shares during the quarter. Affinity Asset Advisors LLC owned 5.30% of Avalo Therapeutics worth $4,092,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently bought and sold shares of the stock. Walleye Capital LLC acquired a new stake in shares of Avalo Therapeutics in the fourth quarter valued at approximately $145,000. Bank of Montreal Can bought a new stake in shares of Avalo Therapeutics during the 4th quarter valued at $446,000. Finally, Geode Capital Management LLC lifted its stake in shares of Avalo Therapeutics by 937.0% in the 4th quarter. Geode Capital Management LLC now owns 104,853 shares of the company's stock valued at $779,000 after purchasing an additional 94,742 shares during the period. 87.06% of the stock is owned by institutional investors.

Avalo Therapeutics Stock Down 4.8 %

NASDAQ:AVTX traded down $0.22 during trading hours on Friday, hitting $4.41. 73,888 shares of the company were exchanged, compared to its average volume of 53,923. The company has a fifty day simple moving average of $6.90 and a 200 day simple moving average of $8.70. Avalo Therapeutics, Inc. has a one year low of $4.31 and a one year high of $17.49.

Analyst Upgrades and Downgrades

AVTX has been the subject of a number of recent analyst reports. Jefferies Financial Group started coverage on Avalo Therapeutics in a research note on Tuesday, March 25th. They issued a "buy" rating and a $23.00 price target for the company. Stifel Nicolaus began coverage on shares of Avalo Therapeutics in a research note on Tuesday, March 25th. They issued a "buy" rating and a $36.00 target price for the company. Wedbush reissued an "outperform" rating and set a $18.00 price target on shares of Avalo Therapeutics in a research report on Thursday, March 20th. HC Wainwright restated a "neutral" rating on shares of Avalo Therapeutics in a research report on Thursday, March 20th. Finally, Piper Sandler assumed coverage on Avalo Therapeutics in a report on Friday, February 28th. They issued an "overweight" rating and a $48.00 price target for the company. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $33.00.

Avalo Therapeutics Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.